Aiolos Bio Overview
- Year Founded
-
2023
- Status
-
Acquired/Merged
- Employees
-
30
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.13B
Aiolos Bio General Information
Description
Operator of a clinical-stage biopharmaceutical company intended to focus on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. The company aims to revolutionize the treatment landscape for respiratory disease and inflammatory conditions by providing products for a range of immune conditions, including asthma, rheumatoid arthritis, IPF, and more, enabling patients and caregivers with more efficacious therapies that significantly reduce treatment burden.
Contact Information
Website
www.aiolosbio.comCorporate Office
- 200 Clarendon Street
- Boston, MA 02116
- United States
Corporate Office
- 200 Clarendon Street
- Boston, MA 02116
- United States
Aiolos Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 14-Feb-2024 | $1.13B | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 24-Oct-2023 | Completed | Clinical Trials - Phase 2 |
Aiolos Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Series A | 151,067,219 | $0.000100 | $1.19 | $1.19 | 1x | $1.19 | 61.36% |
Aiolos Bio Comparisons
Industry
Financing
Details
Aiolos Bio Competitors (3)
One of Aiolos Bio’s 3 competitors is Dimerix, a Formerly VC-backed company based in Fitzroy, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dimerix | Formerly VC-backed | Fitzroy, Australia | ||||
| IVERIC bio | Formerly VC-backed | Parsippany, NJ | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA |
Aiolos Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aiolos Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aiolos Bio Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atlas Venture | Venture Capital | Minority | ||
| Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Gershon Capital | Venture Capital | Minority | ||
| RA Capital Management | Venture Capital | Minority |
Aiolos Bio FAQs
-
When was Aiolos Bio founded?
Aiolos Bio was founded in 2023.
-
Where is Aiolos Bio headquartered?
Aiolos Bio is headquartered in Boston, MA.
-
What is the size of Aiolos Bio?
Aiolos Bio has 30 total employees.
-
What industry is Aiolos Bio in?
Aiolos Bio’s primary industry is Biotechnology.
-
Is Aiolos Bio a private or public company?
Aiolos Bio is a Private company.
-
What is the current valuation of Aiolos Bio?
The current valuation of Aiolos Bio is .
-
What is Aiolos Bio’s current revenue?
The current revenue for Aiolos Bio is .
-
How much funding has Aiolos Bio raised over time?
Aiolos Bio has raised $245M.
-
Who are Aiolos Bio’s investors?
Atlas Venture, Bain Capital Life Sciences, Forbion, Gershon Capital, and RA Capital Management are 5 of 6 investors who have invested in Aiolos Bio.
-
Who are Aiolos Bio’s competitors?
Dimerix, IVERIC bio, and Apellis Pharmaceuticals are competitors of Aiolos Bio.
-
When was Aiolos Bio acquired?
Aiolos Bio was acquired on 14-Feb-2024.
-
Who acquired Aiolos Bio?
Aiolos Bio was acquired by GSK.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
